Pricing Log in Create free account
Friday 6 November 2026 Export WST’s income statement to Excel — free account

West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue
+8.69%
EPS
+56.7%
Free cash flow
+12.3%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

400.17 7.69 +1.96%
Market cap
$27.3B
P/E
43.8×
Fwd P/E
48.1×
Dividend yield
0.22%
F-score
8/9
Altman Z
13.89
Beneish M
−2.79
Dividend safety
100/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

West Pharmaceutical Services, Inc. 10-Q filed Oct 23, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 24, 2025: 2 added · 2 removed · 29 modified; 36 with only figures updated

  1. Modified · Macroeconomic Factors

    In recent months, the U.S. government has imposed additional tariffs and trade restrictions on certain goods produced outside of the United States. In response to these actions, certain jurisdictions, including China, Mexico, Canada and the European Union, in which we operate have imposed or are considering imposing tariffs and restrictions on certain goods produced in the United States. We continue to monitor this dynamic situation to assess the impact of these tariffs on our business and actions we can take to minimize their impact. Based on the information available at this time, we do not believe the impact will be material to our 2025 results.